Jobs
-
Satsuma Pharmaceuticals said that the Phase 3 EMERGE trial of its STS101 dihydroergotamine nasal powder for the treatment of migraine failed to demonstrate statistically significant improvement in either pain relief or the patient’s most bothersome… Read more . . .
-
Inhaled drug developer Savara has announced the departures of its co-founders, CEO Rob Neville and President and Chief Business Officer Taneli Jouhikainen, who have resigned “to pursue other opportunities,” according to the company. Matthew Pauls, who… Read more . . .
-
AZTherapies has announced the initiation of a Phase 2a clinical trial of its ALZT-OP1a inhaled cromolyn in patients with mild- to moderate-stage amyotrophic lateral sclerosis (ALS). The randomized open-label trial is expected to enroll 80… Read more . . .
-
GlaxoSmithKline and Innoviva have announced that the Trelegy Ellipta fluticasone furoate / umeclidinium / vilanterol DPI has been approved by the FDA for the treatment of asthma in adult patients. The approved doses for the… Read more . . .
-
Marinomed Biotech said that it has submitted an MAA via the decentralized marketing authorization procedure for a xylometazoline decongestant nasal spray formulated with the company’s Carragelose red algae extract. The company currently markets a range… Read more . . .
-
Destiny Pharma and SporeGen have agreed to co-develop a bacillus nasal spray as a prophylactic for prevention of COVID-19, with much of the project cost covered by an £800,000 grant from Innovate UK. Pan Group… Read more . . .
-
Verona Pharma has initiated a study of its ensifentrine MDI in patients hospitalized with COVID-19 at the University of Alabama Birmingham (UAB), the company said. The company has been developing the MDI formulation for the… Read more . . .
-
US biotech Diomics Corporation has announced plans to develop a prophylactic nasal spray against COVID-19 using antibodies licensed from Active Motif. According to the company, the Dioguard nasal spray, currently in in vitro testing, uses… Read more . . .
-
According to Aridis Pharmaceuticals, the FDA has agreed to allow a Phase 2a trial of the company’s AR-501 nebulized formulation of gallium citrate for the treatment of lung infections in cystic fibrosis patients to skip… Read more . . .
-
Auris Medical said that the first part of the Phase 2 TRAVERS study of its AM-125 intranasal betahistine for the treatment of vertigo has demonstrated a dose dependent improvement in balance up to 2.4 times… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 9-June 10: Nasal Drug Delivery Symposium: Current Status and Future Opportunities, Stockholm, Sweden
June 10: SMI.London 2026, London, UK